Drugs / Trifluridine-Tipiracil
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT07527858 | May 2026 → Dec 2028 expected | colorectal cancer | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05468892 | Oct 2019 → May 2022 | malignant colon neoplasm | University of Campania Luigi Vanvitelli | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06197425 | May 2026 → May 2032 expected | colorectal adenocarcinoma | Centre Hospitalier Universitaire Dijon | Recruiting | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1/2 | NCT04626635 Background | Dec 2020 → Nov 2026 expected | cancer | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06607458 Background | Aug 2025 → Dec 2026 expected | colorectal cancer | Delcath Systems Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06887218 Comparator | May 2025 → Dec 2028 expected | colorectal cancer | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05278351 Comparator | Jul 2022 → Apr 2024 | colorectal cancer | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT06356311 Comparator | May 2024 → Jan 2027 expected | gastroesophageal cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine-Tipiracil | “Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5...” NCT05468892 ↗8“Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging” NCT06197425 ↗ “Trifluridine Tipiracil Tablets 35mg/m2 BID D1-D5, D8-D12 oral, Q4W” NCT05278351 ↗ |
| Route | Oral | “Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily” NCT05468892 ↗ |